Insider Selling: Medpace (NASDAQ:MEDP) General Counsel Sells $7,357,050.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) General Counsel Stephen Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Medpace Trading Up 1.2%

NASDAQ:MEDP opened at $450.82 on Thursday. Medpace Holdings, Inc. has a twelve month low of $293.20 and a twelve month high of $628.92. The company has a 50-day moving average of $457.02 and a 200-day moving average of $510.24. The firm has a market cap of $12.88 billion, a price-to-earnings ratio of 28.34, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the previous year, the firm earned $3.67 EPS. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Analysts Set New Price Targets

MEDP has been the subject of a number of recent research reports. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and cut their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Truist Financial reduced their target price on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. BMO Capital Markets dropped their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a report on Friday, February 13th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $467.08.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Levi & Korsinsky, Schall, DJS, Pomerantz, Glancy Prongay Wolke & Rotter, and others, reminded investors about a pending class action against Medpace and the June 8 lead-plaintiff deadline, keeping litigation risk in focus.
• Negative Sentiment: The repeated lawsuit alerts may reinforce concerns that Medpace could face financial liability and management distraction if the allegations gain traction, which can pressure the stock.
• Neutral Sentiment: Separately, Medpace General Counsel Stephen Ewald disclosed a sale of 16,349 shares at $450 each. Insider selling can attract attention, but this transaction alone does not necessarily signal a change in the company’s fundamentals.

Hedge Funds Weigh In On Medpace

A number of hedge funds have recently modified their holdings of MEDP. Optiver Holding B.V. purchased a new stake in shares of Medpace during the third quarter worth $27,000. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace in the 4th quarter worth about $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace during the 4th quarter worth about $30,000. Finally, Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter worth about $35,000. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.